Results 131 to 140 of about 178,847 (197)
Designer Dynamic DNA Nanoaggregate in Living Cell for Mitochondrial Energy Restriction
This study presents the Tech‐tetrahedron, a designer dynamic DNA nanoaggregate engineered for precise mitochondrial energy restriction. Its trinity‐functionalized design integrates navigable unit, telomerase‐activated latch, and self‐assembly module.
Ruijia Deng +12 more
wiley +1 more source
Deletion of Lymphatic PD-L1 Protects Mice From Severe Autoimmune Encephalitis. [PDF]
Wang Z +8 more
europepmc +1 more source
Placental Site Trophoblastic Tumor Acquires Immune Functions by Incorporating Host Maternal Genes
PSTT cells, through cell fusion with B cells, incorporate abundant non‐inherited maternal genes that are detectable by DNIMA. These hybrid cells acquire immunotherapy‐resistant genetic changes and increase the expression of B cell‐derived immune‐related molecules such as Ig, HLA, LILRB, SIGLEC10, and so on, creating an immunotolerant environment around
Kyosuke Kagami +15 more
wiley +1 more source
Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective. [PDF]
Wu J +7 more
europepmc +1 more source
We introduced genetically encodable, receptor‐independent nanobody‐CPP chimeras, termed endobodies, as robust and modular membrane protein degraders. Additionally, proteasome‐targeting domain (PTD)‐tethered endobody demonstrates further enhanced degradation potency.
Chengjian Zhou +3 more
wiley +1 more source
Engineering T cells with a novel PD-L1-specific TCR targeting immune and cancer cells. [PDF]
Lisle TL +5 more
europepmc +1 more source
Integrated clinical and mechanistic analyses identify GALNT7 as a ferroptosis‐suppressive regulator associated with immunotherapy resistance in non‐small cell lung cancer. GALNT7 depletion promotes lipid peroxidation, mitochondrial dysfunction, and ferroptosis, enhances CD8+ T‐cell activation and IFN‐γ production, and sensitizes tumors to PD‐1 blockade,
Jiadi Gan +11 more
wiley +1 more source
Differentiation state affects PD-L1 expression in cutaneous melanoma: a systematic review. [PDF]
Sævarsson T +3 more
europepmc +1 more source
This study introduces a biomimetic “nanofusion” platform that integrates the biostability of threose nucleic acids (TNA) with homotypic cell‐membrane cloaking to combat drug‐resistant TNBC. By leveraging a non‐canonical membrane‐fusion pathway for direct cytosolic delivery, the platform bypasses endosomal sequestration. To achieve potent AKT2 silencing
Wei Zheng +7 more
wiley +1 more source
Strategies to target PD-1/PD-L1 in the tumor microenvironment. [PDF]
Kui Y, Tong F, Zhang R, Dong X, Wang J.
europepmc +1 more source

